Media
-
Racura Oncology Looks To Accelerate Clinical Development Of Bisantrene
Racura Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Racura received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene, which is undergoing Phase II trials specifically for Acute Myeloid Leukemia. The clinical-stage biopharmaceutical…
-
‘Significant Potential’: This ASX Stock Is Winning The Racura To Make Cancer Care Heart-Safe
For all the excitement about curing cancer or the disease going into remission, the relief for some patients can often be short-lived if the treatment leaves them with other potentially long-term health repercussions. Cardiovascular health problems are typically the most common, but Racura Oncology (ASX:RAC) is working to minimise damage to the heart linked to almost all…
-
What’s In Store For 2024: Racura Oncology
2024 Preview: Racura Oncology (ASX:RAC) from Stockhead on Vimeo. Stockhead’s Ashtyn Hiron sits down with Racura Oncology (ASX:RAC) CEO Daniel Tillett to close the books on 2023 and gain a sneak peek into what’s around the corner. The clinical stage biopharmaceutical company makes drugs that are designed to treat cancer better with its lead asset, bisantrene (RC220) , currently in Phase…
